News & Media

News Updates

Thanet Earth Adopts INBS' Fingerprint Drug Test to Enhance Workplace Safety

UK’s Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions’ Fingerprint Drug Test to Enhance Workplace Safety

New York, September 25, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet Earth, the UK’s largest greenhouse complex, has adopted its Intelligent Fingerprinting Drug Screening System for in-house drug testing.  “We are thrilled to partner with Intelligent…

READ MORE >
INBS Reports Fiscal 2024 Q4

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

NEW YORK, September 19, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update. Fiscal fourth quarter revenue totalled $0.73 million, an increase of 64% compared…

READ MORE >
INBS Announces Preliminary 2024 Revenue Growth of 148% YoY

Intelligent Bio Solutions Inc. Announces Preliminary Full Fiscal Year 2024 Revenue Growth of 148% Year-Over-Year

NEW YORK, September 9, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal fourth quarter and full year ended June 30, 2024, of $0.73 million and $3.11 million respectively. This represents an increase year-over-year of 64%…

READ MORE >
INBS-Method-Comparison

Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission

NEW YORK, September 05, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its progress toward completion of the clinical study plan required for its FDA 510(k) submission. In August 2024, INBS announced its partnership with CenExel to perform the method comparison study as part of…

READ MORE >
INBS Reports 118% Growth in Customer Employee Base

Intelligent Bio Solutions Inc. Reports 118% Year-Over-Year Growth in Customer Employee Base, Reaching an Estimated Total of 1.4 Million Employees

NEW YORK, September 03, 2024 – Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leader in non-invasive drug testing technology, today announced significant growth in its customer employee base, reporting a 118% fiscal year-over-year increase in the estimated total number of employees across its customer base. As of June 30, 2024, the…

READ MORE >
INBS Drug Screening Reader

Intelligent Bio Solutions Inc. (INBS) Achieves Major Milestone with Over 1,000 Installed Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024

New York, August 21, 2024 — Intelligent Bio Solutions Inc. (NASDAQ: INBS)(“INBS” or the “Company”), a leading innovator in non-invasive drug testing technology, today announced the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers with customers as of June 30, 2024. This achievement marks a significant milestone for INBS, underscoring the growing demand for the…

READ MORE >
INBS Partners with CenExel to Conduct Clinical Study

Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway

NEW YORK, August 1, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with CenExel, a nationwide clinical research site network, to perform a method comparison clinical study as part of the Company’s FDA 510(k) clinical study plan….

READ MORE >
INBS Announces Qabas as Exclusive Distributor in Saudi Arabia

Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia 

New York, July 24, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced QabasTech (“Qabas”) as its exclusive distributor in Saudi Arabia. This partnership marks further growth for INBS in the country, aligning with its ambitious infrastructure projects and commitment…

READ MORE >
INBS Advances FDA 510(k) Pathway with Biocompatibility Study

­­­Intelligent Bio Solutions Inc. Advances on FDA 510(k) Pathway with Biocompatibility Study Success

NEW YORK, 18 July, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of biocompatibility testing of its Intelligent Fingerprinting Drug Screening System, a pivotal phase in the clinical study plan required for FDA 510(k) regulatory clearance. …

READ MORE >
INBS Strengthens UK Market Position with Addition of Key Manufacturing Accounts

Intelligent Bio Solutions Strengthens UK Market Position with Addition of Key Manufacturing Account

New York, July 9, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of several key accounts in the UK manufacturing sector. This announcement follows recent successes in the warehouse and logistics, transport and infrastructure, and retail sectors…

READ MORE >
INBS Completes In-Clinic Portion of PK Study

Intelligent Bio Solutions Completes In-Clinic Portion of Pharmacokinetic (PK) Study Part of 510(k) Pathway for Approval & Commences Review of Results

New York, June 28, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of the in-clinic portion of its pharmacokinetic (PK) study, a core component of the Company’s clinical study plan for its 510(k) pathway for regulatory…

READ MORE >
INBS Expands Presence in the UK Retail Sector

Intelligent Bio Solutions Expands Presence in the UK Retail Sector with Major Account Acquisitions

New York, June 27, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the expansion of its customer network within the UK retail sector. This includes the adoption of INBS’ Intelligent Fingerprinting Drug Screening System by three prominent UK retailers, among the largest and…

READ MORE >
warehouse

Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and Logistics Sector

New York, June 20, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has successfully signed two new major customer accounts within the UK warehouse and logistics sector within the past three months. These accounts employ more than…

READ MORE >

Media

Media Contact

Sign Up

Subscribe to receive the latest news and updates from Intelligent Bio Solutions.